February 5, 2026 — Leads & Copy — Infleqtion, a global leader in quantum sensing and computing, has been selected to advance to Phase 3 of the Wellcome Leap Quantum for Bio (Q4Bio) Challenge.
The company’s quantum software team, collaborating with the University of Chicago (UChicago) and Massachusetts Institute of Technology (MIT), will participate in the global program focused on demonstrating quantum-enabled solutions for human health. Infleqtion is preparing to go public through a merger with Churchill Capital Corp X (NASDAQ: CCCX).
Pranav Gokhale, CTO of Infleqtion, said Phase 3 will allow testing of quantum-enabled biomarker discovery end to end. He added the company is applying its hybrid quantum–classical workflow to real oncology data to evaluate whether quantum methods can improve feature selection on current hardware.
Biomarker discovery, the identification of molecular, genetic, or image-based features to help diagnose cancer, guide treatment, or predict patient response, requires analyzing high-dimensional, multimodal clinical datasets. Traditional tools often struggle to capture subtle or higher-order interactions across these data types. The Wellcome Leap Q4Bio program is directly targeting this challenge, supporting teams working to demonstrate quantum-enabled methods for human health within the next five years.
Gokhale noted the project works because clinicians, biologists, and quantum scientists are designing the solution together. He added that the collaboration ensures the algorithms address genuine clinical needs while remaining implementable on near-term quantum hardware.
Across Phases 1 and 2, the Infleqtion-led team built a hybrid quantum–classical workflow designed to handle the complexity of modern biomedical data. The approach combines organized preprocessing of DNA, RNA, and pathology image features with a higher-order optimization method that can capture interactions often missed by traditional techniques. The team also developed Hyper-RQAOA, a quantum routine tailored to current and near-term hardware that leverages parameter transfer techniques to greatly improve efficiency.
Phase 3 transitions the effort from controlled simulations to experiments on real quantum processors. To succeed, teams must show meaningful performance on current devices and demonstrate how their methods will scale to the next generation of quantum systems. Infleqtion’s team will use this stage to tackle forecasting treatment response in head-and-neck cancer using a curated cohort from UChicago. The goal is to determine whether quantum-in-the-loop analysis can reveal clinically useful biomarker sets that support precision oncology decisions.
The company released the team’s flagship research paper, Toward Quantum-Enabled Biomarker Discovery: An Outlook from Q4Bio, which is available on arXiv.
Infleqtion designs and builds quantum computers, precision sensors, and quantum software for governments, enterprises, and research institutions. The company’s commercial portfolio includes quantum computers as well as quantum RF systems, quantum clocks, and inertial navigation solutions. Infleqtion announced in September 2025 it plans to go public via a merger with Churchill X (NASDAQ: CCCX).
Source: Infleqtion
